文献速递颈动脉与弓上血管

经颈动脉血运重建时代的再手术颈动脉内膜剥脱术与初次颈动脉内膜剥脱术的结局比较

Outcomes of redo vs primary carotid endarterectomy in the transcarotid artery revascularization era.
PubMed 文献 · J Vasc Surg · 2025-02-19

基于血管质量倡议2003至2023年198,150例颈动脉内膜剥脱术患者,再手术颈动脉内膜剥脱术(rCEA)占1.6%,比例从2.3%降至1.0%(P<.001)。2016至2023年rCEA的院内卒中/死亡比值比高于初次手术(aOR 2.45,95%CI 1.85-3.18,P<.001),无症状与有症状患者中均存在该关联。

要点

  • rCEA占比在研究期间从2.3%降至1.0%(P<.001),同期rCEA后卒中/死亡呈上升趋势(P=.019)。
  • 2016至2023年rCEA的卒中/死亡高于pCEA(3.1% vs 1.3%;aOR 2.45,95%CI 1.85-3.18)。
  • 有症状患者rCEA院内卒中/死亡超过6%,作者建议对此类患者应非常谨慎地筛选。

核心结论

  • 随着血管内治疗选择增多,美国每年rCEA比例下降,而rCEA结局恶化,卒中/死亡随时间上升,主要由有症状患者结局更差驱动。
  • 无症状患者rCEA的卒中/死亡在血管外科学会指南范围内,rCEA、颈动脉支架置入或药物治疗的选择应在医患共同决策后进行。
  • 有症状患者rCEA院内卒中/死亡超过6%,应非常谨慎地筛选,因为部分患者不太可能从rCEA获益。

研究设计与样本

  • 回顾性分析血管质量倡议2003至2023年所有接受颈动脉内膜剥脱术的患者,分为pCEA与rCEA两组。
  • 采用Cochrane-Armitage趋势检验分析rCEA比例变化,Mann-Kendall趋势检验分析rCEA围手术期结局随时间的变化。
  • 采用多因素logistic回归比较2003至2015年和2016至2023年两个队列中rCEA与pCEA的院内卒中/死亡、卒中、死亡及卒中/死亡/心肌梗死,并按术前症状分层分析。

主要发现

  • 共198,150例颈动脉内膜剥脱术患者,98.4%为pCEA,1.6%为rCEA。
  • 研究期间rCEA比例从2.3%降至1.0%(P<.001);rCEA后卒中/死亡随时间上升(P=.019),而死亡率改善(P=.009)。
  • 2003至2015年rCEA较pCEA卒中/死亡更高(2.4% vs 1.2%;aOR 1.81,95%CI 1.14-2.73,P=.007),该差异仅见于无症状患者(2.3% vs 1.1%;aOR 2.03,95%CI 1.19-3.25,P=.006),有症状患者无差异(3.0% vs 2.0%;aOR 1.37,95%CI 0.51-3.01,P=.50)。
  • 2016至2023年rCEA较pCEA卒中/死亡更高(3.1% vs 1.3%;aOR 2.45,95%CI 1.85-3.18,P<.001),无症状患者(1.9% vs 1.0%;aOR 1.95,95%CI 1.29-2.82,P<.001)和有症状患者(6.3% vs 2.0%;aOR 3.23,95%CI 2.17-4.64,P<.001)中均存在该关联。

关键数值与推荐

  • 2016至2023年有症状患者rCEA院内卒中/死亡为6.3%,pCEA为2.0%(aOR 3.23,95%CI 2.17-4.64,P<.001)。
  • 无症状患者rCEA的卒中/死亡在血管外科学会指南范围内,rCEA、颈动脉支架置入或药物治疗的选择应在医患共同决策后进行。
  • 有症状患者rCEA院内卒中/死亡超过6%,应非常谨慎地筛选。

临床怎么用

  • 作者认为,无症状患者rCEA、颈动脉支架置入或药物治疗的选择应在医患共同决策后进行。
  • 作者建议,有症状患者应非常谨慎地筛选rCEA,因为部分患者不太可能从rCEA获益。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Outcomes following redo carotid endarterectomy (rCEA) have been shown to be worse than those after primary CEA (pCEA). Additional research has shown that outcomes are better with transcarotid artery revascularization (TCAR) for restenosis after CEA compared with rCEA and transfemoral carotid artery stenting; however, not all patients are eligible for TCAR or transfemoral carotid artery stenting. Given the increasing utilization of endovascular techniques, this study aims to evaluate changes in outcomes of rCEA vs pCEA before and after the approval of TCAR by the United States Food and Drug Administration in 2015. METHODS: All patients between 2003 and 2023 who underwent CEA in the Vascular Quality Initiative were included and categorized as pCEA or rCEA. Cochrane-Armitage trend testing was used to examine trends in proportion of rCEA compared with pCEA, and the Mann-Kendall trend test was used for perioperative outcomes following rCEA overtime. Multivariable logistic regression was used to compare in-hospital stroke/death, stroke, death, and stroke/death/myocardial infarction following rCEA vs pCEA after stratifying patients into two cohorts: 2003 to 2015 and 2016 to 2023 (before and after introduction of TCAR). Analysis was also performed based on preoperative symptoms. RESULTS: Of 198,150 patients undergoing CEA, 98.4% were pCEA and 1.6% were rCEA. During the study period, the proportion of rCEA in the Vascular Quality Initiative decreased from 2.3% to 1.0% as endovascular methods became more available (P < .001). Trend testing of individual outcomes showed an increase in the stroke/death rate following rCEA over time (P = .019) despite an improvement in the death rate (P = .009). From 2003 to 2015, patients undergoing rCEA had higher odds of stroke/death compared with pCEA (2.4% vs 1.2%; adjusted odds ratio [aOR], 1.81; 95% confidence interval [CI], 1.14-2.73; P = .007). Higher stroke/death rates after rCEA persisted only in asymptomatic patients (2.3% vs 1.1%; aOR, 2.03; 95% CI, 1.19-3.25; P = .006); however, there was no difference in symptomatic patients (3.0% vs 2.0%; aOR, 1.37; 95% CI, 0.51;3.01; P = .50). In the late period, rCEA had higher odds of stroke/death compared with pCEA (3.1% vs 1.3%; aOR, 2.45; 95% CI, 1.85-3.18; P < .001), and the association was seen in asymptomatic patients (1.9% vs 1.0%; aOR, 1.95; 95% CI, 1.29-2.82; P < .001) and symptomatic patients (6.3% vs 2.0%; aOR, 3.23; 95% CI, 2.17-4.64; P < .001). CONCLUSIONS: The proportion of rCEAs done yearly in the United States has been decreasing as endovascular options became available. As the rate of rCEA has decreased, outcomes have been worsening, with an increasing stroke/death rate seen over time, driven primarily by worse outcomes in symptomatic patients. Stroke/death rates for asymptomatic patients fall within Society for Vascular Surgery guidelines, and so the choice between rCEA, CAS, or medical management should be made after shared decision-making between a patient and their surgeon. However, with an in-hospital stroke death rate of over 6% symptomatic patients should be selected very carefully, as some are less likely to benefit from rCEA.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Caron E, Yadavalli SD, Manchella M, et al. Outcomes of redo vs primary carotid endarterectomy in the transcarotid artery revascularization era. J Vasc Surg. 2025. PMID: 39984141. doi:10.1016/j.jvs.2025.02.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。